High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma

Philip Jay Bierman, Julie Marie Vose, J. R. Anderson, M. R. Bishop, A. Kessinger, James Olen Armitage

Research output: Contribution to journalArticle

240 Citations (Scopus)

Abstract

Purpose: This study evaluated the results of high-dose therapy followed by autologous bone marrow or peripheral-blood stem-cell transplantation for patients with follicular low-grade non-Hodgkin's lymphoma. Patients and Methods: We performed a retrospective review of 100 patients undergoing autologous transplantation far follicular low-grade lymphoma between April 22, 1983 and December 31, 1993. Results: Sixty-seven patients remained alive and 48 were failure-free. The median follow-up duration of surviving patients was 2.6 years (range, 1.0 to 11.7). There were eight (8%) deaths within 100 days of transplantation. Six additional patients died of nonrelapse causes up to 912 days after transplantation. Overall survival at 4 years was estimated to be 65% (95% confidence interval [CI], 54% to 75%) and failure-free survival was estimated to be 44% (95% CI, 33% to 55%). There was no definite evidence of a plateau in the failure-free survival curve. The only factor significantly associated with overall survival and failure-free survival was the number of chemotherapy regimen received before transplantation. No significant differences in outcome were observed between patients with follicular small cleaved-cell lymphoma and follicular mixed lymphoma, or between patients who received peripheral-blood stem-cell transplants and unpurged autologous bone marrow transplants. Conclusion: Prolonged failure- free survival is possible following high-dose therapy and autologous hematopoietic rescue for follicular low-grade lymphoma. It is unclear whether patients are cured with this therapy or if survival is prolonged.

Original languageEnglish (US)
Pages (from-to)445-450
Number of pages6
JournalJournal of Clinical Oncology
Volume15
Issue number2
DOIs
StatePublished - Feb 1997

Fingerprint

Non-Hodgkin's Lymphoma
Follicular Lymphoma
Survival
Therapeutics
Transplantation
Bone Marrow
Confidence Intervals
Transplants
Peripheral Blood Stem Cell Transplantation
Autologous Transplantation
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. / Bierman, Philip Jay; Vose, Julie Marie; Anderson, J. R.; Bishop, M. R.; Kessinger, A.; Armitage, James Olen.

In: Journal of Clinical Oncology, Vol. 15, No. 2, 02.1997, p. 445-450.

Research output: Contribution to journalArticle

@article{b77a1e8be9384233846e1b4f1a4f3a1f,
title = "High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma",
abstract = "Purpose: This study evaluated the results of high-dose therapy followed by autologous bone marrow or peripheral-blood stem-cell transplantation for patients with follicular low-grade non-Hodgkin's lymphoma. Patients and Methods: We performed a retrospective review of 100 patients undergoing autologous transplantation far follicular low-grade lymphoma between April 22, 1983 and December 31, 1993. Results: Sixty-seven patients remained alive and 48 were failure-free. The median follow-up duration of surviving patients was 2.6 years (range, 1.0 to 11.7). There were eight (8{\%}) deaths within 100 days of transplantation. Six additional patients died of nonrelapse causes up to 912 days after transplantation. Overall survival at 4 years was estimated to be 65{\%} (95{\%} confidence interval [CI], 54{\%} to 75{\%}) and failure-free survival was estimated to be 44{\%} (95{\%} CI, 33{\%} to 55{\%}). There was no definite evidence of a plateau in the failure-free survival curve. The only factor significantly associated with overall survival and failure-free survival was the number of chemotherapy regimen received before transplantation. No significant differences in outcome were observed between patients with follicular small cleaved-cell lymphoma and follicular mixed lymphoma, or between patients who received peripheral-blood stem-cell transplants and unpurged autologous bone marrow transplants. Conclusion: Prolonged failure- free survival is possible following high-dose therapy and autologous hematopoietic rescue for follicular low-grade lymphoma. It is unclear whether patients are cured with this therapy or if survival is prolonged.",
author = "Bierman, {Philip Jay} and Vose, {Julie Marie} and Anderson, {J. R.} and Bishop, {M. R.} and A. Kessinger and Armitage, {James Olen}",
year = "1997",
month = "2",
doi = "10.1200/JCO.1997.15.2.445",
language = "English (US)",
volume = "15",
pages = "445--450",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma

AU - Bierman, Philip Jay

AU - Vose, Julie Marie

AU - Anderson, J. R.

AU - Bishop, M. R.

AU - Kessinger, A.

AU - Armitage, James Olen

PY - 1997/2

Y1 - 1997/2

N2 - Purpose: This study evaluated the results of high-dose therapy followed by autologous bone marrow or peripheral-blood stem-cell transplantation for patients with follicular low-grade non-Hodgkin's lymphoma. Patients and Methods: We performed a retrospective review of 100 patients undergoing autologous transplantation far follicular low-grade lymphoma between April 22, 1983 and December 31, 1993. Results: Sixty-seven patients remained alive and 48 were failure-free. The median follow-up duration of surviving patients was 2.6 years (range, 1.0 to 11.7). There were eight (8%) deaths within 100 days of transplantation. Six additional patients died of nonrelapse causes up to 912 days after transplantation. Overall survival at 4 years was estimated to be 65% (95% confidence interval [CI], 54% to 75%) and failure-free survival was estimated to be 44% (95% CI, 33% to 55%). There was no definite evidence of a plateau in the failure-free survival curve. The only factor significantly associated with overall survival and failure-free survival was the number of chemotherapy regimen received before transplantation. No significant differences in outcome were observed between patients with follicular small cleaved-cell lymphoma and follicular mixed lymphoma, or between patients who received peripheral-blood stem-cell transplants and unpurged autologous bone marrow transplants. Conclusion: Prolonged failure- free survival is possible following high-dose therapy and autologous hematopoietic rescue for follicular low-grade lymphoma. It is unclear whether patients are cured with this therapy or if survival is prolonged.

AB - Purpose: This study evaluated the results of high-dose therapy followed by autologous bone marrow or peripheral-blood stem-cell transplantation for patients with follicular low-grade non-Hodgkin's lymphoma. Patients and Methods: We performed a retrospective review of 100 patients undergoing autologous transplantation far follicular low-grade lymphoma between April 22, 1983 and December 31, 1993. Results: Sixty-seven patients remained alive and 48 were failure-free. The median follow-up duration of surviving patients was 2.6 years (range, 1.0 to 11.7). There were eight (8%) deaths within 100 days of transplantation. Six additional patients died of nonrelapse causes up to 912 days after transplantation. Overall survival at 4 years was estimated to be 65% (95% confidence interval [CI], 54% to 75%) and failure-free survival was estimated to be 44% (95% CI, 33% to 55%). There was no definite evidence of a plateau in the failure-free survival curve. The only factor significantly associated with overall survival and failure-free survival was the number of chemotherapy regimen received before transplantation. No significant differences in outcome were observed between patients with follicular small cleaved-cell lymphoma and follicular mixed lymphoma, or between patients who received peripheral-blood stem-cell transplants and unpurged autologous bone marrow transplants. Conclusion: Prolonged failure- free survival is possible following high-dose therapy and autologous hematopoietic rescue for follicular low-grade lymphoma. It is unclear whether patients are cured with this therapy or if survival is prolonged.

UR - http://www.scopus.com/inward/record.url?scp=0031026736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031026736&partnerID=8YFLogxK

U2 - 10.1200/JCO.1997.15.2.445

DO - 10.1200/JCO.1997.15.2.445

M3 - Article

C2 - 9053464

AN - SCOPUS:0031026736

VL - 15

SP - 445

EP - 450

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -